Christina Woopen Urszula Konofalska Katja Akgün Tjalf Ziemssen
10.3389/fimmu.2022.897748
Front Immunol
2022 Jul 25;13:897748.
case report coronavirus disease (covid-19) multiple sclerosis neutralizing antibody prophylaxis severe acute respiratory syndrome coronavirus 2 (sars-cov-2) sphingosine-1-receptor modulators (s1pr) vaccination
CC BY
https://pubmed.ncbi.nlm.nih.gov/35958567/
Antibodies, Monoclonal, Humanized / administration & dosage Antibodies, Monoclonal, Humanized / adverse effects COVID-19 / prevention & control Multiple Sclerosis / drug therapy Pre-Exposure Prophylaxis
Antibodies, Monoclonal, Humanized / administration & dosage Antibodies, Monoclonal, Humanized / adverse effects COVID-19 / prevention & control Multiple Sclerosis / drug therapy Pre-Exposure Prophylaxis Case Reports Antibodies, Monoclonal Antibodies, Neutralizing Antibodies, Viral Humans SARS-CoV-2 Sphingosine-1-Phosphate Receptors Vaccination Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antibodies, Neutralizing Antibodies, Viral Sphingosine-1-Phosphate Receptors tixagevimab cilgavimab sotrovimab imdevimab casirivimab SARS-CoV-2 variants
PMC9360990
35958567
Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses
2022